Rare diseases
Investigational molecules
Locations
Study of JNJ-68284528 for Treating Multiple Myeloma in Patients Using Ciltacabtagene Autoleucel and Drug Combination
BelgiumStudy Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma
BelgiumStudy on the Effectiveness of Talquetamab and Teclistamab in First-Line Treatment for Transplant-Eligible Multiple Myeloma Patients
DenmarkStudy on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients
FranceStudy Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant
AustriaStudy of Venetoclax, Daratumumab, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
DenmarkStudy Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma
AustriaStudy Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma
BelgiumStudy on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis
BelgiumStudy Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation
CzechiaStudy Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments
AustriaStudy on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination
AustriaTell us about your condition – we search every trial in Europe and connect you with the right site.
